Risperdal Lawsuit News: Mother Alleges Risperdal, Invega Caused Teen Son to Develop Gynecomastia, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) December 04, 2014 -- A Louisiana mother has filed a new Risperdal lawsuit (http://www.risperdallawsuit2014.com/) that alleges her teenaged son developed gynecomastia (male breast growth) due to his use of Risperdal, as well as Invega, another atypical antipsychotic drug marketed by Johnson & Johnson’s Janssen Pharmaceuticals unit, Bernstein Liebhard LLP reports. According to a November 25th filing in U.S. District Court, Middle District of Louisiana, her son was prescribed Risperdal, Risperdal Consta and Invega by several doctors. Among other things, the lawsuit claims that the manufacturers of the drugs violated federal law by failing to fully and accurately disclose information related to their adverse effects in labeling, package inserts and promotional materials. (Case 3:14-cv-00741-JWD-RLB)
“Our Firm is representing a number of men and boys who allegedly developed gynecomastia due to their use of Risperdal and Invega that raise many of the same questions at issue in this complaint. We are monitoring the ongoing litigation surrounding these medications very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal or Invega.
Risperdal and Invega Litigation
According to court documents, more than 1,000 Risperdal and Invega lawsuits are now pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All of these lawsuits were filed on behalf of individuals who allegedly suffered serious side effects related to their use, including gynecomastia, a condition marked by the excess development of breast tissue in boys and men. Among other things, the complaints accuse Johnson & Johnson and Janssen of improperly marketing the medications for off-label pediatric uses. The gynecomastia claims also accuse the companies of failing to warn that Risperdal and Invega can cause the body to produce excess amounts of prolactin, a hormone tied to female breast growth and lactation. (In Re: Risperdal Litigation, Case Number 100300296).
In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to resolve criminal and civil charges levied by the U.S. Department of Justice regarding the marketing of several medications, including Risperdal and Invega. Among other things, the companies were accused of improperly promoting the antipsychotic drugs for unapproved uses, and of paying kickbacks to physicians who prescribed Risperdal. According to the Department of Justice, the settlement ranked among the largest involving healthcare fraud in U.S. history.
Victims of gynecomastia allegedly related to the use of Risperdal or Invega may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Risperdal Gynecomastia Lawsuit Center, http://www.risperdallawsuit2014.com/, +1 800-511-5092, [email protected]
Share this article